{"name":"Eisai Co., Ltd.","slug":"eisai","ticker":"ESALY","exchange":"OTC","domain":"eisai.com","description":"Eisai Co., Ltd. is a Japanese pharmaceutical company specializing in oncology, neurology, and infectious diseases. The company's key products include Lenvima, Halaven, and Halodip. Eisai has a significant presence in the global pharmaceutical market, with a focus on innovative treatments for patients with high unmet medical needs.","hq":"Tokyo, Japan","founded":1947,"employees":"~75,000","ceo":"Haruo Naito","sector":"Specialty Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"153.4B","metrics":{"revenue":7000000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Lenvima","genericName":"LENVATINIB","slug":"lenvatinib","revenue":1053000000,"yoyGrowth":0,"percentOfTotal":38.2},{"name":"Aricept","genericName":"DONEPEZIL","slug":"donepezil","revenue":800000000,"yoyGrowth":0,"percentOfTotal":29.1},{"name":"Leqembi","genericName":"LECANEMAB","slug":"lecanemab","revenue":500000000,"yoyGrowth":0,"percentOfTotal":18.2},{"name":"Halaven","genericName":"ERIBULIN","slug":"eribulin","revenue":400000000,"yoyGrowth":0,"percentOfTotal":14.5}],"timeline":[{"date":"1990-01-01","label":"Hexalen first approved","drug":"Hexalen","drugSlug":"altretamine","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Aricept first approved","drug":"Aricept","drugSlug":"donepezil","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Ontak first approved","drug":"Ontak","drugSlug":"denileukin-diftitox","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Ontak first approved","drug":"Ontak","drugSlug":"e7777","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Banzel first approved","drug":"Banzel","drugSlug":"rufinamide","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Halaven first approved","drug":"Halaven","drugSlug":"eribulin","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Belviq first approved","drug":"Belviq","drugSlug":"lorcaserin","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Lenvima first approved","drug":"Lenvima","drugSlug":"lenvatinib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Dayvigo first approved","drug":"Dayvigo","drugSlug":"lemborexant","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Leqembi first approved","drug":"Leqembi","drugSlug":"lecanemab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-31","label":"Lenvima PHASE3 readout","drug":"Lenvima","drugSlug":"lenvatinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-30","label":"Leqembi PHASE3 readout","drug":"Leqembi","drugSlug":"lecanemab","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Lenvima patent cliff ($1.4B at risk)","drug":"Lenvima","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Halaven patent cliff ($1.1B at risk)","drug":"Halaven","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":1453000000,"percentOfTotal":52.8,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Lenvima","genericName":"LENVATINIB","slug":"lenvatinib","indication":"Endometrial carcinoma progressing after chemotherapy","status":"marketed","revenue":1053000000},{"name":"Halaven","genericName":"ERIBULIN","slug":"eribulin","indication":"Liposarcoma","status":"marketed","revenue":400000000},{"name":"Hexalen","genericName":"ALTRETAMINE","slug":"altretamine","indication":"Malignant tumor of ovary","status":"marketed"},{"name":"E7389 (Eribulin Mesylate)","genericName":"E7389 (Eribulin Mesylate)","slug":"e7389-eribulin-mesylate","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"Ontak","genericName":"DENILEUKIN DIFTITOX","slug":"denileukin-diftitox","indication":"Primary cutaneous T-cell lymphoma","status":"marketed"},{"name":"Ontak","genericName":"E7777","slug":"e7777","indication":"Primary cutaneous T-cell lymphoma","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":1300000000,"percentOfTotal":47.2,"drugCount":8,"colorKey":"immunology","drugs":[{"name":"Aricept","genericName":"DONEPEZIL","slug":"donepezil","indication":"Alzheimer's disease","status":"marketed","revenue":800000000},{"name":"Leqembi","genericName":"LECANEMAB","slug":"lecanemab","indication":"Alzheimer's disease","status":"marketed","revenue":500000000},{"name":"Banzel","genericName":"RUFINAMIDE","slug":"rufinamide","indication":"Seizures associated with Lennox-Gastaut Syndrome","status":"marketed"},{"name":"E3810","genericName":"E3810","slug":"e3810","indication":"Schizophrenia","status":"phase_3"},{"name":"BOTULINUM TOXIN TYPE B","genericName":"BOTULINUM TOXIN TYPE B","slug":"botulinum-toxin-type-b","indication":"Cervical dystonia","status":"marketed"},{"name":"E2020-Donepezil hydrochloride","genericName":"E2020-Donepezil hydrochloride","slug":"e2020-donepezil-hydrochloride","indication":"Moderate to severe dementia of the Alzheimer's type","status":"phase_2"},{"name":"LEQEMBI","genericName":"LECANEMAB-IRMB","slug":"lecanemab-irmb","indication":"Alzheimer's disease","status":"marketed"},{"name":"Mecobalamin IM injection","genericName":"Mecobalamin IM injection","slug":"mecobalamin-im-injection","indication":"Vitamin B12 deficiency with neurological manifestations","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":18,"colorKey":"neuroscience","drugs":[{"name":"Dayvigo","genericName":"LEMBOREXANT","slug":"lemborexant","indication":"Insomnia","status":"marketed"},{"name":"E0671","genericName":"E0671","slug":"e0671","indication":"Other","status":"marketed"},{"name":"E2020","genericName":"E2020","slug":"e2020","indication":"Other","status":"marketed"},{"name":"E2027","genericName":"E2027","slug":"e2027","indication":"Other","status":"phase_2"},{"name":"MENATETRANONE","genericName":"MENATETRANONE","slug":"menatetranone","indication":"Other","status":"marketed"},{"name":"E2022- New Formula Tape","genericName":"E2022- New Formula Tape","slug":"e2022-new-formula-tape","indication":"Other","status":"phase_1"},{"name":"Equfina","genericName":"Equfina","slug":"equfina","indication":"Other","status":"phase_2"},{"name":"Eszopiclone 1 mg- Elderly","genericName":"Eszopiclone 1 mg- Elderly","slug":"eszopiclone-1-mg-elderly","indication":"Insomnia in elderly patients (sleep onset and sleep maintenance)","status":"phase_3"},{"name":"Eszopiclone 2 mg- Elderly","genericName":"Eszopiclone 2 mg- Elderly","slug":"eszopiclone-2-mg-elderly","indication":"Other","status":"phase_3"},{"name":"Eszopiclone 2 mg- Non-elderly","genericName":"Eszopiclone 2 mg- Non-elderly","slug":"eszopiclone-2-mg-non-elderly","indication":"Insomnia (sleep initiation and maintenance) in non-elderly adults","status":"phase_3"},{"name":"Eszopiclone 3 mg- Non-elderly","genericName":"Eszopiclone 3 mg- Non-elderly","slug":"eszopiclone-3-mg-non-elderly","indication":"Insomnia (sleep initiation and maintenance) in non-elderly adults","status":"phase_3"},{"name":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","genericName":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","slug":"group-a-e5501-5mg-then-20mg-then-40-mg-then-5mg","indication":"Other","status":"phase_1"},{"name":"HOPE","genericName":"HOPE","slug":"hope","indication":"Other","status":"marketed"},{"name":"Mecobalamin IV Injection","genericName":"Mecobalamin IV Injection","slug":"mecobalamin-iv-injection","indication":"Other","status":"marketed"},{"name":"Mecobalamin IV or IM injection","genericName":"Mecobalamin IV or IM injection","slug":"mecobalamin-iv-or-im-injection","indication":"Other","status":"marketed"},{"name":"Selbex","genericName":"Selbex","slug":"selbex","indication":"Other","status":"marketed"},{"name":"Tasurgratinib","genericName":"Tasurgratinib","slug":"tasurgratinib","indication":"Other","status":"phase_1"},{"name":"lysozyme 90 mg","genericName":"lysozyme 90 mg","slug":"lysozyme-90-mg","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Belviq","genericName":"LORCASERIN","slug":"lorcaserin","indication":"Obesity","status":"marketed"},{"name":"E7090","genericName":"E7090","slug":"e7090","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Eperisone hydrochloride","genericName":"Eperisone hydrochloride","slug":"eperisone-hydrochloride","indication":"Muscle tension and spasticity associated with musculoskeletal disorders","status":"phase_3"},{"name":"Eperisone hydrochloride and Diclofenac sodium","genericName":"Eperisone hydrochloride and Diclofenac sodium","slug":"eperisone-hydrochloride-and-diclofenac-sodium","indication":"Acute musculoskeletal pain and muscle spasticity","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Lysozyme hydrochloride","genericName":"Lysozyme hydrochloride","slug":"lysozyme-hydrochloride","indication":"Bacterial infections (topical/local use)","status":"marketed"}]}],"pipeline":[{"name":"Lenvima","genericName":"LENVATINIB","slug":"lenvatinib","phase":"marketed","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells.","indications":["Endometrial carcinoma progressing after chemotherapy","Follicular thyroid carcinoma","Hurthle cell carcinoma of thyroid","Liver cell carcinoma","Papillary thyroid carcinoma"],"catalyst":""},{"name":"Aricept","genericName":"DONEPEZIL","slug":"donepezil","phase":"marketed","mechanism":"Aricept works by blocking the enzyme that breaks down a key neurotransmitter in the brain, acetylcholine.","indications":["Alzheimer's disease","Moderate to Severe Alzheimer's Type Dementia"],"catalyst":""},{"name":"Leqembi","genericName":"LECANEMAB","slug":"lecanemab","phase":"marketed","mechanism":"Leqembi works by binding to and removing amyloid beta A4 protein from the brain, which is thought to contribute to the progression of Alzheimer's disease.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Halaven","genericName":"ERIBULIN","slug":"eribulin","phase":"marketed","mechanism":"Halaven works by binding to tubulin beta, disrupting microtubule dynamics and leading to cell death.","indications":["Liposarcoma","Metastatic Breast Carcinoma"],"catalyst":""},{"name":"Banzel","genericName":"RUFINAMIDE","slug":"rufinamide","phase":"marketed","mechanism":"Banzel works by stabilizing inactivated sodium channels in the brain, reducing the frequency of seizures.","indications":["Seizures associated with Lennox-Gastaut Syndrome"],"catalyst":""},{"name":"Belviq","genericName":"LORCASERIN","slug":"lorcaserin","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2C","indications":["Obesity"],"catalyst":""},{"name":"Dayvigo","genericName":"LEMBOREXANT","slug":"lemborexant","phase":"marketed","mechanism":"Dayvigo blocks the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles.","indications":["Insomnia"],"catalyst":""},{"name":"E0671","genericName":"E0671","slug":"e0671","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E2020","genericName":"E2020","slug":"e2020","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E2027","genericName":"E2027","slug":"e2027","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E3810","genericName":"E3810","slug":"e3810","phase":"phase_3","mechanism":"E3810 is a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide signaling in the brain.","indications":["Schizophrenia","Parkinson's disease psychosis"],"catalyst":""},{"name":"E7090","genericName":"E7090","slug":"e7090","phase":"phase_2","mechanism":"E7090 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Hexalen","genericName":"ALTRETAMINE","slug":"altretamine","phase":"marketed","mechanism":"Cytochrome P450 1A2","indications":["Malignant tumor of ovary"],"catalyst":""},{"name":"MENATETRANONE","genericName":"MENATETRANONE","slug":"menatetranone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BOTULINUM TOXIN TYPE B","genericName":"BOTULINUM TOXIN TYPE B","slug":"botulinum-toxin-type-b","phase":"marketed","mechanism":"Botulinum toxin type B blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Strabismus","Hyperhidrosis","Migraine prophylaxis"],"catalyst":""},{"name":"E2020-Donepezil hydrochloride","genericName":"E2020-Donepezil hydrochloride","slug":"e2020-donepezil-hydrochloride","phase":"phase_2","mechanism":"Donepezil hydrochloride is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease.","indications":["Moderate to severe dementia of the Alzheimer's type"],"catalyst":""},{"name":"E2022- New Formula Tape","genericName":"E2022- New Formula Tape","slug":"e2022-new-formula-tape","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E7389 (Eribulin Mesylate)","genericName":"E7389 (Eribulin Mesylate)","slug":"e7389-eribulin-mesylate","phase":"phase_3","mechanism":"Eribulin is a microtubule dynamics inhibitor that suppresses microtubule growth and induces apoptosis in cancer cells.","indications":["Metastatic breast cancer","Liposarcoma","Other solid tumors (in clinical development)"],"catalyst":""},{"name":"Eperisone hydrochloride","genericName":"Eperisone hydrochloride","slug":"eperisone-hydrochloride","phase":"phase_3","mechanism":"Eperisone hydrochloride is a muscle relaxant that reduces muscle tension by inhibiting monoamine oxidase and enhancing noradrenergic and serotonergic neurotransmission in the central nervous system.","indications":["Muscle tension and spasticity associated with musculoskeletal disorders","Cervical spondylosis with muscle stiffness","Lower back pain with muscle tension"],"catalyst":""},{"name":"Eperisone hydrochloride and Diclofenac sodium","genericName":"Eperisone hydrochloride and Diclofenac sodium","slug":"eperisone-hydrochloride-and-diclofenac-sodium","phase":"phase_3","mechanism":"This combination product uses eperisone as a muscle relaxant and diclofenac as an NSAID to reduce muscle tension and inflammation-related pain.","indications":["Acute musculoskeletal pain and muscle spasticity","Pain associated with muscle tension and inflammation"],"catalyst":""},{"name":"Equfina","genericName":"Equfina","slug":"equfina","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eszopiclone 1 mg- Elderly","genericName":"Eszopiclone 1 mg- Elderly","slug":"eszopiclone-1-mg-elderly","phase":"phase_3","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","indications":["Insomnia in elderly patients (sleep onset and sleep maintenance)"],"catalyst":""},{"name":"Eszopiclone 2 mg- Elderly","genericName":"Eszopiclone 2 mg- Elderly","slug":"eszopiclone-2-mg-elderly","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eszopiclone 2 mg- Non-elderly","genericName":"Eszopiclone 2 mg- Non-elderly","slug":"eszopiclone-2-mg-non-elderly","phase":"phase_3","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.","indications":["Insomnia (sleep initiation and maintenance) in non-elderly adults"],"catalyst":""},{"name":"Eszopiclone 3 mg- Non-elderly","genericName":"Eszopiclone 3 mg- Non-elderly","slug":"eszopiclone-3-mg-non-elderly","phase":"phase_3","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.","indications":["Insomnia (sleep initiation and maintenance) in non-elderly adults"],"catalyst":""},{"name":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","genericName":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","slug":"group-a-e5501-5mg-then-20mg-then-40-mg-then-5mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HOPE","genericName":"HOPE","slug":"hope","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LEQEMBI","genericName":"LECANEMAB-IRMB","slug":"lecanemab-irmb","phase":"marketed","mechanism":"Amyloid beta A4 protein","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Lysozyme hydrochloride","genericName":"Lysozyme hydrochloride","slug":"lysozyme-hydrochloride","phase":"marketed","mechanism":"Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection.","indications":["Bacterial infections (topical/local use)","Dry eye syndrome (as a component of tear substitutes)"],"catalyst":""},{"name":"Mecobalamin IM injection","genericName":"Mecobalamin IM injection","slug":"mecobalamin-im-injection","phase":"marketed","mechanism":"Mecobalamin is an active form of vitamin B12 that replenishes cellular cobalamin stores and restores normal methylation and energy metabolism.","indications":["Vitamin B12 deficiency with neurological manifestations","Peripheral neuropathy associated with B12 deficiency","Subacute combined degeneration","Pernicious anemia with neurological complications"],"catalyst":""},{"name":"Mecobalamin IV Injection","genericName":"Mecobalamin IV Injection","slug":"mecobalamin-iv-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mecobalamin IV or IM injection","genericName":"Mecobalamin IV or IM injection","slug":"mecobalamin-iv-or-im-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ontak","genericName":"DENILEUKIN DIFTITOX","slug":"denileukin-diftitox","phase":"marketed","mechanism":"Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells.","indications":["Primary cutaneous T-cell lymphoma","Refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"Ontak","genericName":"E7777","slug":"e7777","phase":"marketed","mechanism":"Interleukin-2 receptor","indications":["Primary cutaneous T-cell lymphoma","Refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"Selbex","genericName":"Selbex","slug":"selbex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tasurgratinib","genericName":"Tasurgratinib","slug":"tasurgratinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"lysozyme 90 mg","genericName":"lysozyme 90 mg","slug":"lysozyme-90-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-02","type":"earnings","headline":"Eisai Co., Ltd. Announces FY2023 Financial Results","summary":"Eisai reported a net sales increase of 10.1% to ¥1,144.9 billion for the fiscal year ended March 31, 2024.","drugName":"","sentiment":"positive"},{"date":"2023-12-20","type":"deal","headline":"Eisai and Biogen Announce Collaboration to Develop and Commercialize Alzheimer's Disease Treatment","summary":"Eisai and Biogen have entered into a collaboration to develop and commercialize a potential treatment for Alzheimer's disease.","drugName":"","sentiment":"positive"},{"date":"2023-08-04","type":"regulatory","headline":"FDA Approves Lenvima for First-Line Treatment of Hepatocellular Carcinoma","summary":"The U.S. FDA has approved Lenvima (lenvatinib) for the first-line treatment of hepatocellular carcinoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTFBDOTMwOElQbkhvME01bXRRY25BOXpROXZJVE1HVG9UM1FvbE9Zb204NEQ1Yk5pMXNJOUt2cFZHYS1GMWNtX2kxUDIwdw?oc=5","date":"2026-04-03","type":"pipeline","source":"meyka.com","summary":"Body and Mind Inc. (BMMJ) Competitors - meyka.com","headline":"Body and Mind Inc. (BMMJ) Competitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE1sZ1NYZExxa1I2WmNGSEVmOEpkcFl2YzdCS2J4dmVDM1dmM1hGWFQzRl8tOF8xcHVpVjhWeVZ4NmotU3E1Y3BySl9JQ3E?oc=5","date":"2026-04-02","type":"pipeline","source":"meyka.com","summary":"BioNxt Solutions Inc. (XPHYF) Competitors - meyka.com","headline":"BioNxt Solutions Inc. (XPHYF) Competitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQdS1KcFFLNW1uX1JnMWU0UGo3VnFQOVlsXzUwaVdudzdtWFVNZnc4dTZMbEFBZU1nWk1MSjVUdTUtVmxnV1VkZWJpQmdMLWF5dFd2SlZ1VGFCdXdnWTJVV1AzeDI5OFBKTlF1MUJGUlI4Zm1SYUYyTC11aTB4ZzEtMHJ0VmdCMDYzUnZKblpPSXI5cTJDdnE1c2Q5SEpYWWlRdGVTUzFLNWJxRmYyNWptMk9JQnU3SXJQcDA2dFRFUFF1blJnWGFoUFdfNUJ2dnQ0d2UzN1hidUt2T2ZKQXhSSGFZcDR1Q1Vha0RwUGNDT1dTMk9meGg5d1paN1FMblhIQl8wdWNpMkZOSW5PbHlfdzNhekxIdw?oc=5","date":"2026-02-06","type":"earnings","source":"FinancialContent","summary":"FinancialContent - Biogen (BIIB) Q4 Earnings Preview: The \"New Biogen\" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage - FinancialContent","headline":"FinancialContent - Biogen (BIIB) Q4 Earnings Preview: The \"New Biogen\" Emerges as Alzheimer's and Rare Disease Pipelines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNSlVYRUY0ZEtLX1BnSVRQRldCRDUyaFBfYWFkNGdMbk9CR1RQUjFRSjJ1Y2NjQ0stMjZKSDM5emQ3T2ptdVItcjdaUjBhaVA3dFVzT3R6WldfSFBFRWdoNV80dnZ3TjBrUlZKdXRfZTJ1cUVDYk5FaTcxZTdYd1drcHU0REU5LUtxd1JWUzg4aFAxSUZkYlF3OVdwS2FzME9idWl0U0FXWElFMWFYYnhuZUZFT29kR0pCZmZJRGowMzJrUHVzYkRGVA?oc=5","date":"2026-01-20","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Eisai Co Ltd: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS","headline":"The Truth About Eisai Co Ltd: Why Everyone Is Suddenly Paying Attention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9BMTFXcld2R25pcmNrRUM4eUhIRjltUkVwRUdCNjVFODNvSTVvMWNvU1lNRVRuRWttcXIwZHY5Uk9HSkFPekpuQXNkSy03NlQycEIzUw?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ESALY Stock Price, News & Analysis - Stock Titan","headline":"ESALY Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNOWZFRzNRdkNQZm1TUkFPa0w5cnJRbk9QVU43dTRWd21PYTU5b0xKaEV6OEhxNXJLblA1Rmd4VUJPdEFnLVo2c1lrWkhoZDJKdlJUV2tBSk91THZhUVdQZTloaFdSOEFXeGNORnczR0JCYnlLbXJCWExTVFRCT0EyYkVHOEJkZw?oc=5","date":"2025-04-11","type":"pipeline","source":"Future Market Insights","summary":"Vascular Dementia Treatment Market 2025 to 2035 - Future Market Insights","headline":"Vascular Dementia Treatment Market 2025 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9oSmpFT1p2ajRiRTFGMkV3MnlEV2ltTWhKZE5scXFpVEcwclU0dnQyZDFhWHg2emltTTJkWkNhbGlxakdqejlEN2JMS1QzTzMyY1dvemVndGFkNFNsSkYtcg?oc=5","date":"2024-03-29","type":"pipeline","source":"Eisai","summary":"Eisai India’s Initiatives for Eliminating Lymphatic Filariasis - Eisai","headline":"Eisai India’s Initiatives for Eliminating Lymphatic Filariasis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBsdFZBT0NDeXZRM0w3bnhpUThHdjAyNngxTWtuckJVVjdySHZVeXZwWmdBdTJfWG9EallTWjBlM1NQMU5mb2sxaGdVM0hWVlJ6UUlxSEdCdnpSUUJYSW9za2Q1ZUJndFo0RnZ6a2NxTl9FVm9iYVBuWUVVNA?oc=5","date":"2022-03-22","type":"regulatory","source":"Yahoo Autos","summary":"Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab - Yahoo Autos","headline":"Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE43OTFocGtJMFg4Wkl0UGZZZkk5a01qZ3czNThXS2R0a3hSNHFmeFU3UXQyRUhXa19YZ2xXT29UYW5GaHphaG5JS05jVkVXeTdLSjVGMm5nYVpDR3M?oc=5","date":"2020-07-28","type":"pipeline","source":"Eisai","summary":"EISAI AND DeNA TO PROVIDE SMARTPHONE APP “EASIIT APP” THROUGH BUSINESS ALLIANCE AGREEMENT - Eisai","headline":"EISAI AND DeNA TO PROVIDE SMARTPHONE APP “EASIIT APP” THROUGH BUSINESS ALLIANCE AGREEMENT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNWERoYVdPa0ZDU25kLVVFMnQ1Q09qU2M4OHVuUEl2OTJRbnhNVFAzZWJVR1cxekdidnJkRmstN1lQRFFkMlZWX3RqaEtlYmlIc0czRkR2UVY3aTBJc2NSRG5IM0N4dG40bndKWkZoWjZ6OF9BdFBpMDVFaHBXZ0JpWklJWVNjUUM3Z2JxNjUyRlBKSUhab1pVX1lzbjZoa2JwVEhkTXNkakxHRTR3V1dKUGg3cmxQeXN3blpVSXNtXzJxRE9KYmxWblhuU1RlQ1I2UTNwV3c4czJnc1U?oc=5","date":"2019-05-02","type":"pipeline","source":"NutraIngredients.com","summary":"Sparkling water for skin health? Japan pharma firm Eisai adds new flavour to existing range - NutraIngredients.com","headline":"Sparkling water for skin health? Japan pharma firm Eisai adds new flavour to existing range","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQZEZaeWZlNG4zajkxaEZCVmxIY3hNOUowNGNQdGstYVdTRVhWZGlnQmJsNWtadG1EVDhPc0lrRmhiWjFCS2JPbWNIaGFZWld5QkZtQkRvYzdUdFUxVVhld293Szd1b1ptRGpCOUYtUFZBbmRNSUZCRkx1U1BJN2R4el9ETUJYNFhZcTVpVHl2aVN0N2dDeVh5T0FseVk1Z0t4Y2pHNkNoVUVmc21EeGhmcksxaWw0RFpFbUwtdWxXbzROZVpubDd2cjdFelVoUExuOWU2dFlLaHhMSjlCYU5tTjV0cExDa1hBRlV3Z1hZMndQSWREZUJZV2tJNVkxSC1JeTBBMEZybUpfUGt0bEtydzF4RE5QeThjWDhpVjF3dGVFWmRCMGhkQ3I3QVlOOVVaSElTX2hxbw?oc=5","date":"2017-03-21","type":"pipeline","source":"PR Newswire","summary":"Available Now: New Toolkit Encourages Better Communication to Help Prevent Patients from Suffering in Silence Due to Chemotherapy-induced Nausea and Vomiting - PR Newswire","headline":"Available Now: New Toolkit Encourages Better Communication to Help Prevent Patients from Suffering in Silence Due to Che","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1PUkRpRDhJYVIzaDlBajRTNUpsS3hqU0ZxSE9KTUFPMzYyQ3Z2ZVVQVXFGNEpRTzdVOTkxUVp5SmE0RmJxdHkyVXNwTWxvRVNjRE9YMzZ2WQ?oc=5","date":"2008-01-02","type":"pipeline","source":"Pharma Voice","summary":"Midsize Pharma: Moving & Shaking the Industry - Pharma Voice","headline":"Midsize Pharma: Moving & Shaking the Industry","sentiment":"neutral"}],"patents":[{"drugName":"Lenvima","drugSlug":"lenvatinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Halaven","drugSlug":"eribulin","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":37,"phaseCounts":{"marketed":22,"phase_2":4,"phase_3":8,"phase_1":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Merck & Co., Inc.","AstraZeneca PLC","Pfizer Inc."],"therapeuticFocus":["Oncology","Neurology","Infectious Diseases"],"financials":null,"yahoo":null}